Brett Kaplan, M.D.
Chief Operating Officer
Brett brings over 20 years of finance and operations leadership in biotechnology and investment banking. Before joining Climb Bio, Dr. Kaplan served as President, Chief Financial and Corporate Development Officer at Chroma Medicine Inc., which raised approximately $250 million to fund the research and development of their novel epigenetic editors, a new class of genomic medicines. Prior to Chroma, Brett was the Chief Financial Officer of Prevail Therapeutics Inc., , which was acquired by Eli Lilly and Company for $940 million. At Evercore Partners, Brett was a Managing Director advising biopharma clients on strategic and financing transactions. Brett has held other corporate development and strategy positions at Cubist Pharmaceuticals, Biopure Corporation, and Eli Lilly. Brett is currently a director of Myeloid Therapeutics, Inc.
Dr. Kaplan holds an MBBCh and an M.B.A. from the University of Witwatersrand.
What does Climb mean to me? It means traversing with all stakeholders to help patients summit their disease.